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;Reply to Nevin
We agree with Nevin [1] that the post-
marketing surveillance methodology of
our article [2] has similarities with the
analysis published in 1998 by Vanhau-
were and colleagues [3]. We appropriate-
ly referenced the aforementioned paper
in our publication. Our methodology
however, differs in that we separately an-
alyzed maternal, paternal, and both-
parent exposure to meﬂoquine, and the
time period for our study was signiﬁ-
cantly longer (1986–2010) [2]. Further-
more, for comparison, we provided
background rates for pregnancy out-
comes in the general population.
We disagree that the use of this meth-
odology should limit the usefulness of
our data. Pregnant women are routinely
excluded from clinical trials. For many
medications that are initially contraindi-
cated in pregnancy, the use of drug safety
databases constitutes an important tool
for assessing safety during pregnancy.
Our analysis provides physicians and pa-
tients with information for the evaluation
of beneﬁt and risk in women of child-
bearing potential exposed to meﬂoquine.
Our main outcome measures were
descriptive birth defect reporting preva-
lence and types of malformations. We
also provided limited data on fetal loss
and reviewed all literature on this
subject including the references that
Nevin cites in his letter and other refer-
ences that he omitted to mention. Fetal
loss or miscarriage is difﬁcult to quanti-
fy in any population due to ascertain-
ment bias [4], and epidemiological data
from previous studies show varying
results: a Thai study reported an in-
creased risk of miscarriage in 159 meﬂo-
quine prophylaxis users [5], whereas a
second larger study in Malawi showed no
increase in stillbirths in women receiving
meﬂoquine prophylaxis (n = 1032) [6].
Nevin refers to the use of sulfadoxine-
pyrimethamine as intermittent treatment
in the developing world for pregnant
women. This is a separate topic that we did
not address. Our paper is concerned with
malaria prophylaxis in pregnant women
from industrialized countries who cannot
defer travel to malaria-endemic areas.
Dr Nevin’s other letter [7] suggests a
biological mechanism linking meﬂo-
quine to pregnancy loss. This proposed
mechanism warrants further inquiry but
because it is a hypothesis, based on non-
clinical data, it should be interpreted
with caution in the human context.
Various factors, such as age and expo-
sure to malaria, could contribute to the
loss of pregnancy in women traveling to
endemic areas. A large study from
Denmark showed that the risk of spon-
taneous abortion in women aged 20–24
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is 8%–9%, rising with age to 74.7% in
women aged >45 years [8]. Exposure to
malaria further increases the risk of fetal
loss. A recent analysis found that a
single episode of Plasmodium falcipa-
rum or Plasmodium vivax malaria could
cause miscarriage [9].
Malaria in women of childbearing po-
tential needs to be prevented. The recent
data on imported malaria in the US
report 41 cases in pregnant women in
2010, the majority traveling to Africa
and not using a chemoprophylaxis [10].
In 2011, the Food and Drug Administra-
tion reclassiﬁed meﬂoquine from preg-
nancy category C to category B. The
Centers for Disease Control and Preven-
tion recommends meﬂoquine prophy-
laxis in all trimesters of pregnancy for
women who cannot defer travel to high-
risk, malaria-endemic areas [11].
Note
Potential conﬂicts of interest. P. S. has re-
ceived research funding, honoraria for speaking
at conferences, and consultancy fees from F.
Hoffmann-La Roche and honoraria from Glaxo-
SmithKline and Sigma-Tau Pharmaceuticals.
W. A. B., P. S., L. R., G. V.-D., M. T. S., M. S. B.,
H.-G. R., and M. A. are employees of F. Hoff-
mann-La Roche.
All authors have submitted the ICMJE Form
for Disclosure of Potential Conﬂicts of Interest.
Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
Patricia Schlagenhauf,1 William A. Blumentals,2
Pia Suter,2 Loredana Regep,2
Gabriel Vital-Durand,2 Martin T. Schaerer,2
Margarita Suarez Boutros,2 Hans-Georg Rhein,2
and Miriam Adamcova2
1University of Zurich Centre for Travel Medicine,
World Health Organization Collaborating Centre on
Travel and Health, Institute for Social and Preventive
Medicine, Zurich, and 2F. Hoffmann-La Roche,
Basel, Switzerland
References
1. Nevin RL. Limitations of post-marketing sur-
veillance in the analysis of risk of pregnancy
loss associated with maternal meﬂoquine ex-
posure. Clin Infect Dis 2012; 55:1167–8.
2. Schlagenhauf P, Blumentals WA, Suter P,
et al. Pregnancy and fetal outcomes after ex-
posure to meﬂoquine in the pre- and peri-
conception period and during pregnancy.
Clin Infect Dis 2012; 54:e124–31.
3. Vanhauwere B, Maradit H, Kerr L. Postmar-
keting surveillance of prophylactic meﬂo-
quine (Lariam®) use in pregnancy. Am J Trop
Med Hyg 1998; 58:17–21.
4. Committee for Medicinal Products for
Human Use (CHMP). Guideline on the expo-
sure to medical products during pregnancy:
need for post-authorisation data, London:
European Medicines Agency, May 2006. http://
www.ema.europa.eu/docs/en_GB/document_
library/Regulatory_and_procedural_guideline/
2009/11/WC500011303.pdf. Accessed 7 June
2012.
5. Nosten F, ter-Kuile K, Maelankiri L, et al.
Meﬂoquine prophylaxis prevents malaria during
pregnancy: a double-blind, placebo-controlled
study. J Infect Dis 1994; 169:595–603.
6. Steketee RW, Wirima JJ, Slutsker L, Khoro-
mana CO, Heymann DL, Breman JG. Malaria
treatment and prevention in pregnancy: indi-
cations for use and adverse events associated
with use of chloroquine or meﬂoquine. Am J
Trop Med Hyg 1996; 55:50–6.
7. Nevin RL. Meﬂoquine blockade of connexin
43 (Cx43) and risk of pregnancy loss. Placen-
ta 2011; 32:712.
8. Nybo Anderson AM, Wohlfart J, Christens P,
Olsen J, Melbye M. Maternal age and fetal
loss: population based register study. BMJ
2000; 320:1708–12.
9. McGready R, Lee SJ, Wiladphaingern J, et al.
Adverse effects of falciparum and vivax
malaria and the safety of antimalarial treat-
ment in early pregnancy: a population based
study. Lancet Infect Dis 2012; 12:388–96.
10. Mali S, Kachur SP, Arguin PM. Malaria sur-
veillance—United States 2010. MMWR
Morbid Mortal Wkly Rep 2012; 61:1–17.
11. Centers for Disease Control and Prevention
(CDC). Available at: http://www.cdc.gov/
malaria/new_info/2011/meﬂoquine_pregnan
cy.html. Accessed 7 June 2012.
Correspondence. Professor Patricia Schlagenhauf, PhD, Uni-
versity of Zurich Centre for Travel Medicine, WHO Collaborat-
ing Centre for Travellers’ Health, Institute for Social and
Preventive Medicine, Hirschengraben 84, 8001 Zurich, Swit-
zerland (pat@ifspm.uzh.ch).
Clinical Infectious Diseases 2012;55(8):1168–9
© The Author 2012. Published by Oxford University Press on
behalf of the Infectious Diseases Society of America. All
rights reserved. For Permissions, please e-mail: journals.
permissions@oup.com.
DOI: 10.1093/cid/cis611
CORRESPONDENCE • CID 2012:55 (15 October) • 1169
Downloaded from https://academic.oup.com/cid/article-abstract/55/8/1168/340803
by University of Zurich user
on 19 July 2018
